Critically, in contrast to our previous data with constitutively expressing A1R CAR T cells (Fig. 2B), the numbers of NR4A2/hA1R CAR T cells were equivalent to controls in both the spleen and the tumor at up to day 28 post therapy (Fig. 4E–G). The gene discussed is NR4A2; the disease is neoplasm.